Hongxing Pan

4.1k total citations · 2 hit papers
39 papers, 1.8k citations indexed

About

Hongxing Pan is a scholar working on Infectious Diseases, Health and Epidemiology. According to data from OpenAlex, Hongxing Pan has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Infectious Diseases, 11 papers in Health and 10 papers in Epidemiology. Recurrent topics in Hongxing Pan's work include SARS-CoV-2 and COVID-19 Research (21 papers), Vaccine Coverage and Hesitancy (11 papers) and COVID-19 Clinical Research Studies (8 papers). Hongxing Pan is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (21 papers), Vaccine Coverage and Hesitancy (11 papers) and COVID-19 Clinical Research Studies (8 papers). Hongxing Pan collaborates with scholars based in China, Taiwan and United States. Hongxing Pan's co-authors include Fengcai Zhu, Jingxin Li, Kai Chu, Changgui Li, Weidong Yin, Gang Zeng, Yuansheng Hu, Yan Song, Yanjun Zhang and Yaling Hu and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and PLoS ONE.

In The Last Decade

Hongxing Pan

37 papers receiving 1.8k citations

Hit Papers

Safety, tolerability, and... 2020 2026 2022 2024 2020 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
    2020 937 citations Yanjun Zhang, Gang Zeng et al. The Lancet Infectious Diseases profile →
  2. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
    2021 173 citations Gang Zeng, Qianhui Wu et al. The Lancet Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hongxing Pan China 13 1.4k 501 416 228 189 39 1.8k
Yuansheng Hu China 12 1.0k 0.8× 326 0.7× 187 0.4× 123 0.5× 255 1.3× 27 1.4k
Gang Zeng China 11 1.1k 0.8× 380 0.8× 234 0.6× 118 0.5× 121 0.6× 19 1.3k
Yaling Hu China 10 1.5k 1.1× 478 1.0× 103 0.2× 185 0.8× 203 1.1× 21 1.7k
Pedro M. Folegatti United Kingdom 9 834 0.6× 295 0.6× 176 0.4× 160 0.7× 137 0.7× 13 1.1k
Yi Luo United States 18 686 0.5× 286 0.6× 770 1.9× 108 0.5× 108 0.6× 72 1.5k
Samuel M. S. Cheng Hong Kong 17 1.9k 1.4× 160 0.3× 204 0.5× 106 0.5× 342 1.8× 50 2.2k
Minnan Yang China 7 949 0.7× 302 0.6× 79 0.2× 137 0.6× 218 1.2× 8 1.2k
Amy Flaxman United Kingdom 9 783 0.6× 280 0.6× 116 0.3× 151 0.7× 141 0.7× 17 998

Countries citing papers authored by Hongxing Pan

Since Specialization
Citations

This map shows the geographic impact of Hongxing Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongxing Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongxing Pan more than expected).

Fields of papers citing papers by Hongxing Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongxing Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongxing Pan. The network helps show where Hongxing Pan may publish in the future.

Co-authorship network of co-authors of Hongxing Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Hongxing Pan. A scholar is included among the top collaborators of Hongxing Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongxing Pan. Hongxing Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Yuan‐Han, Zhao Hu, Chuanming Wang, et al.. (2025). Bi2O2Se nanosheets coated with rosmarinic acid for colon-targeted treatment of inflammatory bowel disease. Chemical Engineering Journal. 506. 160230–160230.
2.
Cheng, Xin, Hongxing Pan, Zhijian Wang, et al.. (2025). Immunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial. Human Vaccines & Immunotherapeutics. 21(1). 2448405–2448405. 1 indexed citations
3.
Pan, Hongxing, Mingde Tong, Binxuan Huang, et al.. (2024). Fully Biobased High-Strength and High-Toughness Double Cross-Linked Cellulose Hydrogel for Flexible Electrolytes. ACS Sustainable Chemistry & Engineering. 12(50). 18231–18244. 7 indexed citations
4.
Han, Xu, Hongxing Pan, Pengfei Jin, et al.. (2024). A head-to-head comparison of humoral and cellular immune responses of five COVID-19 vaccines in adults in China. Frontiers in Immunology. 15. 1455730–1455730. 1 indexed citations
5.
Zhang, Li, Jing Lü, Haisheng Wu, et al.. (2024). Evaluation of human antibodies from vaccinated volunteers for protection against Yersinia pestis infection. Microbiology Spectrum. 12(10). e0105424–e0105424. 1 indexed citations
6.
7.
Chu, Kai, Yuemei Hu, Hongxing Pan, et al.. (2023). A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age. Human Vaccines & Immunotherapeutics. 19(2). 2235926–2235926. 2 indexed citations
8.
9.
Xin, Qianqian, Qianhui Wu, Xinhua Chen, et al.. (2022). Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials. Nature Communications. 13(1). 3100–3100. 18 indexed citations
10.
Liu, Jiankai, Baoying Huang, Yafei Liu, et al.. (2021). Immunogenicity and Safety of a 3-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. The Journal of Infectious Diseases. 225(10). 1701–1709. 10 indexed citations
11.
Pan, Hongxing, Bihong Huang, K. Y. Chu, et al.. (2021). Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials. Chinese Medical Journal. 28. 28–28. 1 indexed citations
12.
Zeng, Gang, Qianhui Wu, Hongxing Pan, et al.. (2021). Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. The Lancet Infectious Diseases. 22(4). 483–495. 173 indexed citations breakdown →
13.
14.
Zhang, Yanjun, Gang Zeng, Hongxing Pan, et al.. (2020). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases. 21(2). 181–192. 937 indexed citations breakdown →
15.
16.
Pan, Hongxing, Ying Zeng, Yiju Zhang, et al.. (2014). Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. Vaccine. 32(29). 3706–3712. 26 indexed citations
17.
Chen, Yequn, et al.. (2014). Relationship between noninvasive and invasive blood pressure values in end-stage renal disease patients on dialysis. Blood Pressure Monitoring. 19(2). 72–75. 2 indexed citations
18.
Zhu, Fengcai, Zhenglun Liang, Fanyue Meng, et al.. (2012). Retrospective Study of the Incidence of HFMD and Seroepidemiology of Antibodies against EV71 and CoxA16 in Prenatal Women and Their Infants. PLoS ONE. 7(5). e37206–e37206. 55 indexed citations
19.
Zhu, Fengcai, Changgui Li, Hongxing Pan, et al.. (2011). Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial. Chinese Journal of Cancer. 30(8). 559–564. 6 indexed citations
20.
Zhu, Fengcai, Hua Wang, Han-hua Fang, et al.. (2009). A Novel Influenza A (H1N1) Vaccine in Various Age Groups. New England Journal of Medicine. 361(25). 2414–2423. 289 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuansheng Hu Breakdown of academic impact, for papers by Gang Zeng Breakdown of academic impact, for papers by Yaling Hu Breakdown of academic impact, for papers by Pedro M. Folegatti Breakdown of academic impact, for papers by Yi Luo Breakdown of academic impact, for papers by Samuel M. S. Cheng Breakdown of academic impact, for papers by Minnan Yang Breakdown of academic impact, for papers by Amy Flaxman
Rankless by CCL
2026